Dunvegan Associates’s Eli Lilly LLY Stock Holding History

Dunvegan Associates’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$3.49M	Sell	41,378 -423	-1%	-$35.1K	4.1%	5
2015 Q3	$3.5M	Buy	41,801 +1,611	+4%	+$136K	3.99%	6
2015 Q2	$3.35M	Hold	40,190	–	–	3.71%	8
2015 Q1	$2.92M	Sell	40,190 -827	-2%	-$58.9K	2.58%	11
2014 Q4	$2.83M	Sell	41,017 -3,191	-7%	-$215K	2.46%	10
2014 Q3	$2.87M	Sell	44,208 -73	-0.2%	-$4.62K	2.59%	11
2014 Q2	$2.75M	Sell	44,281 -2,877	-6%	-$172K	2.3%	11
2014 Q1	$2.78M	Sell	47,158 -4,061	-8%	-$227K	2.34%	11
2013 Q4	$2.61M	Sell	51,219 -462	-0.9%	-$23.1K	2.15%	15
2013 Q3	$2.6M	Sell	51,681 -193	-0.4%	-$10.1K	1.92%	19
2013 Q2	$2.55M	Buy	+51,874	New	+$2.82M	1.97%	19

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dunvegan Associates's LLY Position: Q4 2015 in Review

Dunvegan Associates reduced its Eli Lilly (LLY) stake by 1% in Q4 2015, selling an estimated $35.1K and leaving 41,378 shares worth $3.49M. The position accounts for 4.1% of the portfolio, ranked #5.

Dunvegan Associates first reported a position in LLY in Q2 2013 and has held it in 11 quarters since. The position peaked at $3.5M in Q3 2015. 1,221 funds tracked by Wall St. Rank hold LLY as of Q4 2015.

Dunvegan Associates held 41,378 shares of Eli Lilly worth $3.49M as of Q4 2015.
Dunvegan Associates sold 423 Eli Lilly shares in Q4 2015, an estimated $35.1K.
Eli Lilly made up 4.1% of Dunvegan Associates's portfolio in Q4 2015, its #5 holding.
Dunvegan Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 11 quarters since.
Dunvegan Associates's Eli Lilly position peaked at $3.5M in Q3 2015.
1,221 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2015.

Based on Dunvegan Associates's 13F filing for Q4 2015, filed 28 Apr 2017.